Bausch + Lomb Corp. develops, manufactures, and markets eye health products. The company is headquartered in Vaughan, Ontario and currently employs 13,500 full-time employees. The company went IPO on 2022-05-06. The company operates through three segments: Vision Care, Pharmaceuticals, and Surgical. Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices for cataract surgery. Its brands consist of PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, ScoutPro, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, INFUSE, and many more.
Follow-Up Questions
Who is the CEO of Bausch + Lomb Corp?
Mr. Brenton Saunders is the Chairman of the Board of Bausch + Lomb Corp, joining the firm since 2023.
What is the price performance of BLCO stock?
The current price of BLCO is $15.38, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Bausch + Lomb Corp?
Bausch + Lomb Corp belongs to Health Care industry and the sector is Health Care
What is Bausch + Lomb Corp market cap?
Bausch + Lomb Corp's current market cap is $5.4B
Is Bausch + Lomb Corp a buy, sell, or hold?
According to wall street analysts, 15 analysts have made analyst ratings for Bausch + Lomb Corp, including 3 strong buy, 7 buy, 8 hold, 1 sell, and 3 strong sell
